Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

ROS1 gene rearrangements have been reported in diverse cancer types including non‐small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma. The tyrosine kinase inhibitors, crizotinib, lorlatinib, and entrectinib, have demonstrated favorable efficacy in treating ROS...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li, Guozhong Jiang
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2020-11-01
Saila:	Molecular Oncology
Gaiak:	crizotinib gene fusion next‐generation sequencing non‐small‐cell lung cancer ROS1
Sarrera elektronikoa:	https://doi.org/10.1002/1878-0261.12789
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!